文献速递神经肿瘤

伊朗恶性胶质瘤流行病学:伊朗国家人群癌症登记处2009—2017年首次报告

Epidemiology of malignant gliomas in Iran: first report of Iranian National Population-based Cancer Registry, 2009-2017.
PubMed 文献 · J Neurosurg · 2024-07-05

该研究基于覆盖伊朗98%人口的伊朗国家人群癌症登记处2009—2017年中枢神经系统肿瘤数据,首次报告伊朗恶性胶质瘤流行病学。共8484例患者,9年总体年龄调整发病率为1.71/10万,胶质母细胞瘤占81.4%,中位总生存13.0个月(95%CI 12.6-13.5)。

要点

  • 2009—2017年伊朗共诊断恶性胶质瘤8484例,总体年龄调整发病率为1.71/10万。
  • 最常见的组织学类型为胶质母细胞瘤,占81.4%。
  • 研究中位总生存为13.0个月(95%CI 12.6-13.5)。

核心结论

  • 本研究是伊朗恶性胶质瘤状况的最新流行病学报告;尽管总体发病率低于发达国家,但多项发现与既往报告一致。

研究设计与样本

  • 基于伊朗国家人群癌症登记处(覆盖伊朗98%人口)2009—2017年记录的中枢神经系统肿瘤数据进行分析,按性别、肿瘤组织学、肿瘤部位和诊断年份计算年龄调整发病率,并进行发病率趋势分析;记录生存数据并使用Cox比例风险模型评估潜在危险因素。

主要发现

  • 2009—2017年伊朗共8484例患者被诊断为恶性胶质瘤。
  • 9年期间恶性胶质瘤总体年龄调整发病率为1.71/10万。
  • 恶性胶质瘤最常见的组织学类型为胶质母细胞瘤,占81.4%。
  • 2009—2012年间恶性胶质瘤发病率显著增加。
  • 研究期间中位总生存为13.0个月(95%CI 12.6-13.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Malignant gliomas constitute the most common type of primary malignant brain tumors. Most previous studies have evaluated the epidemiology of malignant gliomas in developed countries. Hence, there is a lack of evidence in this regard from developing countries. This study is the first epidemiological report on the status of malignant glioma in Iran between 2009 and 2017. METHODS: Data from the Iranian National Population-based Cancer Registry (covering 98% of the Iranian population) on CNS tumors recorded from 2009 to 2017 were used for analysis. Age-adjusted incidence rates were calculated by sex, tumor histology, tumor site, and year of diagnosis. Trend analysis of incidence rates was also performed. Survival data were recorded and the Cox proportional hazards model was used to evaluate underlying risk factors. RESULTS: A total of 8484 patients were diagnosed with malignant glioma between 2009 and 2017 in Iran. The overall age-adjusted incidence rate of malignant gliomas over the 9-year period was 1.71 per 100,000 persons. The most common histology of malignant gliomas was glioblastoma (81.4%). A significant increase in the incidence of malignant gliomas was found between 2009 and 2012. The median overall survival was 13.0 (95% CI 12.6-13.5) months over the study period. Older age groups, higher tumor grade, male sex, the first half of the study period, and receiving no treatment were significantly associated with worse prognoses. CONCLUSIONS: This study is the latest epidemiological report on the status of malignant gliomas in Iran. Although the overall incidence rate was lower than the rates in developed countries, several findings were consistent with those in prior reports.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Tavanaei R, Akhlaghpasand M, Tavanaei D, et al. Epidemiology of malignant gliomas in Iran: first report of Iranian National Population-based Cancer Registry, 2009-2017. J Neurosurg. 2024. PMID: 38968626. doi:10.3171/2024.4.JNS2470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。